➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
McKesson
Colorcon
Mallinckrodt

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZANUBRUTINIB

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Zanubrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03432884 ↗ A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects Completed BeiGene Phase 1 2018-01-25 A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
NCT03465059 ↗ Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function Active, not recruiting BeiGene Phase 1 2018-05-30 This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in subjects with impaired liver function in comparison with healthy subjects
NCT03561298 ↗ A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects Completed BeiGene Phase 1 2018-06-07 This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and breast cancer resistance protein (BCRP) in healthy subjects
NCT03734016 ↗ A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting BeiGene Phase 3 2018-11-05 This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
NCT03824483 ↗ Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Not yet recruiting BeiGene USA, Inc. Phase 2 2019-02-01 The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
NCT03824483 ↗ Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Not yet recruiting Massachusetts General Hospital Phase 2 2019-02-01 The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
NCT03824483 ↗ Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Not yet recruiting Roche-Genentech Phase 2 2019-02-01 The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zanubrutinib

Condition Name

Condition Name for Zanubrutinib
Intervention Trials
Mantle Cell Lymphoma 3
Diffuse Large B Cell Lymphoma 3
Chronic Lymphocytic Leukemia (CLL) 2
Small Lymphocytic Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zanubrutinib
Intervention Trials
Lymphoma 16
Lymphoma, Large B-Cell, Diffuse 7
Lymphoma, B-Cell 6
Leukemia, Lymphocytic, Chronic, B-Cell 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zanubrutinib

Trials by Country

Trials by Country for Zanubrutinib
Location Trials
United States 21
China 12
Australia 8
Japan 7
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zanubrutinib
Location Trials
Florida 4
New Jersey 4
New York 3
Nevada 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zanubrutinib

Clinical Trial Phase

Clinical Trial Phase for Zanubrutinib
Clinical Trial Phase Trials
Phase 3 4
Phase 2 20
Phase 1/Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zanubrutinib
Clinical Trial Phase Trials
Not yet recruiting 19
Recruiting 11
Completed 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zanubrutinib

Sponsor Name

Sponsor Name for Zanubrutinib
Sponsor Trials
BeiGene 16
Peking Union Medical College Hospital 3
German CLL Study Group 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zanubrutinib
Sponsor Trials
Other 19
Industry 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Johnson and Johnson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.